Abstract
Elevated lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular disease (CVD), amplifying high CVD risk in patients with type 2 diabetes (T2DM). The GLP-1 receptor agonist exenatide has been demonstrated to reduce glucose in T2DM.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
